Wednesday, 11 Dec 2019

You are here

Mortality in Gout Increased

Two current articles in the Journal of Rheumatology address issues surrounding mortality risk among those with new and established gout.

Vincent et al assessed predictors of mortality in patients with a recent onset of gout (disease duration < 10 years). They analyzed 295 patients with a mean followup duration of 5.1 years, during which time there were 43 deaths (14.6%).

Factors independently associated with an increased mortality risk included: older age (HR > 9.3 for those over 80 yrs.); Māori or Pacific ethnicity (HR 2.48); loop diuretic use (HR 3.99); elevated serum creatinine and the tophi (HR 2.85).  Amongst these only subcutaneous tophi was the only baseline variable independently associated with both CV death and all cause death.

A gout disease duration < 10 years has an increased risk of death. Subcutaneous tophi at baseline is an independent predictor of mortality, from both CV and non-CV causes.

Kang and Korean investigators also analyzed mortality risk in terms of gender and serum urate (SUA) levels. (Citation source: http://buff.ly/2omFieW

During 12.3 years of followup there was 27,490 deaths, amounting to 6.9% of men and 3.1% of women died.

The bimodal (U shaped) association between SUA levels in men and mortality was not seen in women. Thus a significant interaction of gender was seen with the SUA-mortality association.

Thus a higher mortality rate was seen with very low SUA levels (SUA ≤ 4.0 mg/dl, adjusted HR 1.413) and higher SUA levels in men (> 8.0 mg/dl, adjusted HR 1.140). Women failed to show any significant association between SUA and mortality.

Novel to this study was the observation that lower SUA (after correction) was an independent risk factor for all-cause mortality in men with normal kidney function.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.